4:14 PM ET
8-K
Leadership Change
Aardvark Therapeutics Leadership Change
Aardvark Therapeutics appointed David (Zhongwei) Zhang, Ph.D., MBA, as a Class II director to its Board of Directors, effective October 7, 2026. Dr. Zhang brings over 25 years of experience in clinical strategy and biostatistics from roles at Abivax, Alumis, and MyoKardia. As a non-employee director, he will receive an annual cash retainer of $40,000 and an initial stock option grant valued at $500,000.